A WHO/CONRAD meeting was held in Geneva in October 2001 to consider the importance of these and other data (CONRAD stands for Contraceptive Research and Development Programme). The meeting concluded that nonoxynol-9 should not be used or promoted for the prevention of HIV or sexually acquired infections: condoms are the method of choice. The meeting also concluded that for women at low risk of HIV infection nonoxynol-9 remains a contraceptive option although its effectiveness as a contraceptive when used alone is modest. The rationale for this conclusion is that low-risk women are also likely to be low-frequency users of nonoxynol-9 and hence at low risk of genital lesions which are the putative mechanism for placing women who use nonoxynol-9 frequently at increased HIV risk. However women at high risk of HIV infection and those unaware or unsure of their risk should not use nonoxynol-9 as such use may increase their risk of infection. (excerpt)